April 23rd 2021
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
FDA Approves Targeted Drug to Treat Relapsed or Refractory AML With FLT3 Mutation
December 3rd 2018Once-daily gilteritinib pills have been approved to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Approximately 25% to 30% of patients with AML have this mutation, which is associated with an aggressive form of the disease and carries a higher risk of relapse.
Read More
Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse
December 1st 2018In patients who relapse after allogeneic hematopoietic stem-cell transplantation, the therapeutic benefits that transplantation provide is diminished through mechanisms that remain unclear. A new study analyzed the genetic and epigenetic alterations of leukemic cells to determine any common features of relapse after transplantation
Read More
FDA Approves 2 Treatments in Older Adults With Newly Diagnosed AML
November 27th 2018FDA has recently approved 2 new treatments for patients age 75 and older who are newly diagnosed with AML and have other chronic health conditions or diseases that may mean they cannot use intensive chemotherapy.
Read More
Research to Look Out for at ASH 2018
November 27th 2018From December 1-4, hematology professionals from across the globe will convene in San Diego, California for the American Society of Hematology annual meeting to present and discuss their research and latest developments in malignant and non-malignant hematology. Here’s what to look out for during the meeting.
Read More
AMT-061 Achieves Sufficient Increases in Factor IX Levels for Patients With Hemophilia B
November 23rd 2018AMT-061, an AAV5 vector containing factor IX (FIX)-Padua variant, has been shown to increase FIX activity to threshold FIX levels sufficient to significantly reduce the risk of bleeding events without the risk of adverse immune reactions.
Read More
Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease
November 20th 2018A new investigational drug has demonstrated high response rates in patients with a rare but highly aggressive blood disease that currently has no approved therapies, according to new research led by investigators at The University of Texas MD Anderson Cancer Center.
Read More
Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy
November 17th 2018Since chimeric antigen receptor (CAR) T-cell therapy is still in early development there are benefits and risks that eligible patients will have to weigh, including the durable response against the limited amount of data and toxic side effects, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
Watch
FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma
November 17th 2018The FDA announced Friday it expanded the approved use of brentuximab vedotin (Adcetris) in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma, using a new review process designed to increase efficiency.
Read More
CD47 Antibody With Rituximab Produces Durable Response in R/R Lymphoma
November 15th 2018When used in combination with rituximab, Hu5F9-G4 (5F9), a humanized monoclonal anti-CD47 antibody, promotes durable objective and complete response rates in lymphoma while also having minimal adverse events (AE), according to a phase 1b study published in New England Journal of Medicine.
Read More
Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers
November 13th 2018Patients with blood cancers are burdened with higher costs than patients with other cancers, and spending in blood cancers does not return to precancer levels, according to a new study from the Leukemia & Lymphoma Society.
Read More
Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma
November 7th 2018Daratumumab, a human CD38-directed monoclonal antibody, has been confirmed as safe in a population of heavily pretreated patients with multiple myeloma who received access to the treatment before the medication was commercially available, according to an early access treatment protocol study published in Cancer.
Read More
ALL Treatment May Increase Weight Gain, Suppress Growth in Children, Teens
November 7th 2018Children and adolescents with acute lymphoblastic leukemia (ALL) face an increased risk of obesity and growth impairment from the disease and during ALL treatment, regardless of exposure to cranial irradiation, according to a recent study.
Read More
Authors Find Brentuximab Vedotin Cost-Effective for Treatment of Advanced Hodgkin Lymphoma
October 31st 2018The analysis comes amid a debate set off when CVS Caremark announced that it would allow self-funded insurers to exclude drugs that entered the market above $100,000 per quality-adjusted life year.
Read More
The Evolution of CLL Testing and Treatment Over the Past Decade
October 30th 2018In the last decade, testing for and treatment of chronic lymphocytic leukemia (CLL) had undergone substantial changes with new testing that can personalize therapy and new agents that provide more clinical benefit.
Read More
Massachusetts Medicaid Finds CAR T-Cell Payment Solution While Waiting on CMS
October 25th 2018A life-saving therapy is challenging to administer and poses financial risks for patients and institutions alike. Speakers at the Academy of Managed Care Pharmacy Nexus 2018 address some approaches to paying for it while CMS develops long-term policies.
Read More
Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma
Read More
Three Genetic Types Drive Higher Prevalence of MM in African Americans
October 14th 2018Multiple myeloma (MM) occurs 2 to 3 times more frequently in Americans of African descent than in Americans of European descent, and a new study has identified 3 gene types that account for this disparity.
Read More
Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds
October 11th 2018Tisagenlecleucel's high price is aligned with the benefit the chimeric antigen receptor T-cell therapy provides over a patient's life. Approximately 40% of patients treated are expected to be long-term survivors.
Read More